Atrial FibrillationNCT02407249
Topera C-FIRM Registry
An observational study of Atrial Fibrillation, run by Abbott Medical Devices at 9 sites in 2 countries.
Trial summary
This is a control registry to the E-FIRM registry to track conventional atrial fibrillation (AF) procedures in terms of clinical usage, handling, and the safety and effectiveness for the treatment of symptomatic atrial fibrillation. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Atrial Fibrillation
- How many people
- 73 participants
- Where
- 9 sitesin 2 countries
- Study dates
- Apr 2015to 31 Jul 2018
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Each participating site will enroll 10 consecutive conventional AF patients who are treated according to the standard routine of the center. Patients eligible should be in accordance with the AF Guidelines.
Who may be able to join
- reported incidence of at least 2 documented episodes of symptomatic AF (paroxysmal, persistent or long standing persistent) during the 3 months preceding the initial AF ablation
- attempt of at least one Class I or III anti-arrhythmia drug with failure defined as recurrence of symptomatic AF or adverse drug effect resulting in stopping medication
Who cannot join
- women who are pregnant
- As this is a registry only data of patients will be included who have been treated according to the current AF guidelines and the daily routine of the center.
Trial locations and contacts
9 sites in 2 countries.
9 sites in 2 countries
Germany8 sites
Herz- und Gefäßklinik
Bad Neustadt an der Saale, Bavaria, 97616
Herz- und Diabeteszentrum NRW
Bad Oeynhausen, North Rhine-Westphalia, 32545
Unfallkrankenhaus Berlin
Berlin, 12683
Klinikum Coburg GmbH
Coburg, Bavaria, 96450
Zentrum für klinische Prüfungen in der Facharztzentrum Dresden-Neustadt GbR
Dresden, Saxony, 01099
Städtisches Klinikum Karlsruhe GmbH
Karlsruhe, Baden-Würtemberg, 76133
Herzzentrum Leipzig
Leipzig, Saxony, 04289
Kardiologische Gemeinschaftspraxis am Park Sanssouci
Potsdam, Brandenburg, 14471
About this study
Official title: Control for EU (European Union) Focal Impulse and Rotor Modulation Registry - Topera C-FIRM Registry-
This is a control registry to the E-FIRM registry to track conventional atrial fibrillation (AF) procedures in terms of clinical usage, handling, and the safety and effectiveness for the treatment of symptomatic atrial fibrillation. Conventional AF ablation is defined as pulmonary vein isolation (PVI) and any additional ablation for AF according to the standard routine of the center.
Data items will be collected, if available, consistent and applicable with routine and standard clinical care at each participating site.
Read the detailed description
Prospective and retrospective enrollment possible
- Conditions
- Atrial Fibrillation
- Medical subject headings
- Atrial Fibrillation
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Acute Success
Acute Success was defined as elimination (by ablation) of pulmonary vein triggers during the procedure
Measured: day of procedure
Number of Participants With 12-Month Effectiveness
Effectiveness success was defined as single procedure freedom from AF recurrence at 12-months after index procedure, excluding a 3-month blanking period.
Measured: 12 months after initial AF ablation
Number of Participants With Acute Safety Success
Acute safety success was defined as freedom from Serious Adverse Events 7 days after initial AF ablation
Measured: 7 days after initial AF ablation
Number of Participants With 12-Month Safety Success
12-Month safety success was defined as freedom from Serious Averse Events at 12-months after index procedure
Measured: 12-months after index procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2015 (estimated)
- Study startApr 2015
- Primary completion31 May 2017
- Study completion31 Jul 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- More trials run by Abbott Medical DevicesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Other
- Enrolment
- 73 participants (actual)
Sponsor and investigators
- Lead sponsor
- Abbott Medical Devices
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- I-Med-Pro GmbH
- Responsible party
- Sponsor
- Investigators
- Gerhard Hindricks, Prof. Dr., Principal investigator, Herzzentrum Leipzig - UniversitätsklinikKristin Ruffner, PhD, Study director, Abbott
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02407249
- Sponsor's protocol ID
- C-FIRM-02
- Status last verified
- Oct 2019
- First submitted
- 30 Mar 2015
- Last updated
- 16 Oct 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Control for EU (European Union) Focal Impulse and Rotor Modulation Registry - Topera C-FIRM Registry-
- ClinicalTrials.gov ID
- NCT02407249
- Acronym / sponsor ID
- C-FIRM-02
- Conditions
- Atrial Fibrillation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 73 participants (actual)
- Lead sponsor
- Abbott Medical DevicesIndustry (pharma, biotech, devices)
- Collaborators
- I-Med-Pro GmbH
- Study start
- Apr 2015
- Primary completion
- 31 May 2017 (actual)
- Study completion
- 31 Jul 2018 (actual)
- First posted
- 2 Apr 2015 (estimated)
- Results
- Posted 16 Oct 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a control registry to the E-FIRM registry to track conventional atrial fibrillation (AF) procedures in terms of clinical usage, handling, and the safety and effectiveness for the treatment of symptomatic atrial fibrillation. Conventional AF ablation is defined as pulmonary vein isolation (PVI) and any additional ablation for AF according to the standard routine of the center.
Data items will be collected, if available, consistent and applicable with routine and standard clinical care at each participating site.
Detailed description
Prospective and retrospective enrollment possible
Study design
- Observational model
- Case only
- Time perspective
- Other
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Each participating site will enroll 10 consecutive conventional AF patients who are treated according to the standard routine of the center. Patients eligible should be in accordance with the AF Guidelines.
Key inclusion criteria (2 listed)
- reported incidence of at least 2 documented episodes of symptomatic AF (paroxysmal, persistent or long standing persistent) during the 3 months preceding the initial AF ablation
- attempt of at least one Class I or III anti-arrhythmia drug with failure defined as recurrence of symptomatic AF or adverse drug effect resulting in stopping medication
Key exclusion criteria (2 listed)
- women who are pregnant
- As this is a registry only data of patients will be included who have been treated according to the current AF guidelines and the daily routine of the center.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of Participants With Acute Success
Time frame: day of procedure
Acute Success was defined as elimination (by ablation) of pulmonary vein triggers during the procedure
Number of Participants With 12-Month Effectiveness
Time frame: 12 months after initial AF ablation
Effectiveness success was defined as single procedure freedom from AF recurrence at 12-months after index procedure, excluding a 3-month blanking period.
Number of Participants With Acute Safety Success
Time frame: 7 days after initial AF ablation
Acute safety success was defined as freedom from Serious Adverse Events 7 days after initial AF ablation
Number of Participants With 12-Month Safety Success
Time frame: 12-months after index procedure
12-Month safety success was defined as freedom from Serious Averse Events at 12-months after index procedure
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Atrial Fibrillation
Not yet recruiting
CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke
Atrial Fibrillation (AF)
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
Active, not recruitingObservational study
FARAPULSE™ Pulsed Field Ablation System
Paroxysmal AF
Recruiting
OPTION-EMEA Clinical Trial
Atrial Fibrillation (AF), Stroke Prevention in Patients With Atrial Fibrillation
Active, not recruiting
A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF
Atrial Fibrillation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gerhard Hindricks, Prof. Dr. principal investigator
Herzzentrum Leipzig - Universitätsklinik
Kristin Ruffner, PhD study director
Abbott
9 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation, run by Abbott Medical Devices at 9 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in Germany, Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 16 Oct 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Acute Success (time frame: day of procedure). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2019; AzTrials last refreshed its copy on 28 Oct 2026.